Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia

Relationship with the stage of differentiation and clinical significance

A. Cantu-Rajnoldi, C. Putti, M. Saitta, D. Granchi, R. Foa, R. Schiro, M. Castagni, C. Valeggio, M. Jankovic, R. Miniero, P. Paolucci, G. Basso

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Co-expression of myeloid antigens on the leukaemic blast cells was evaluated in 532 children with a diagnosis of acute lymphoblastic leukaemia (ALL). Using a panel of monoclonal antibodies belonging to CD11b, CD13, CD14, CD15 and CD33 an overall incidence of 4.3% was found, with values ranging between 1.8% for CD14 and 6.1% for CD15. When the data were further dissected, a significantly higher incidence of co-expression was noted in null-ALL (15/70 cases = 21.4%), compared to cases expressing a more mature immunophenotype, i.e. common-ALL (7/394 cases = 1.7%) and T-ALL (1/68 cases = 1.4%) (P <0.001). In null-ALL, 9/15 patients were infants, five of whom with the t(4;11); two further children also had a t(4;11). The clinical outcome of the 23 cases which co-expressed myeloid antigens was unfavourable. Only two of the 15 null-ALL, two of the seven common-ALL and the unique case with T-ALL are in fact in persistent first remission between 19 and 93 months from diagnosis. Though the overall incidence of childhood ALL expressing myeloid antigens is low, the evidence that this co-expression may be related to an unfavourable clinical course and that it more frequently occurs in null-ALL, particularly in the first year of life, suggests that the routine assessment of myeloid antigens may allow to identify a subgroup of childhoold ALL with a poor clinical outcome.

Original languageEnglish
Pages (from-to)40-43
Number of pages4
JournalBritish Journal of Haematology
Volume79
Issue number1
Publication statusPublished - 1991

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antigens
Incidence
Monoclonal Antibodies

ASJC Scopus subject areas

  • Hematology

Cite this

Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia : Relationship with the stage of differentiation and clinical significance. / Cantu-Rajnoldi, A.; Putti, C.; Saitta, M.; Granchi, D.; Foa, R.; Schiro, R.; Castagni, M.; Valeggio, C.; Jankovic, M.; Miniero, R.; Paolucci, P.; Basso, G.

In: British Journal of Haematology, Vol. 79, No. 1, 1991, p. 40-43.

Research output: Contribution to journalArticle

Cantu-Rajnoldi, A, Putti, C, Saitta, M, Granchi, D, Foa, R, Schiro, R, Castagni, M, Valeggio, C, Jankovic, M, Miniero, R, Paolucci, P & Basso, G 1991, 'Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia: Relationship with the stage of differentiation and clinical significance', British Journal of Haematology, vol. 79, no. 1, pp. 40-43.
Cantu-Rajnoldi, A. ; Putti, C. ; Saitta, M. ; Granchi, D. ; Foa, R. ; Schiro, R. ; Castagni, M. ; Valeggio, C. ; Jankovic, M. ; Miniero, R. ; Paolucci, P. ; Basso, G. / Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia : Relationship with the stage of differentiation and clinical significance. In: British Journal of Haematology. 1991 ; Vol. 79, No. 1. pp. 40-43.
@article{0e6d18454d1e44c299b8cf11e52405db,
title = "Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia: Relationship with the stage of differentiation and clinical significance",
abstract = "Co-expression of myeloid antigens on the leukaemic blast cells was evaluated in 532 children with a diagnosis of acute lymphoblastic leukaemia (ALL). Using a panel of monoclonal antibodies belonging to CD11b, CD13, CD14, CD15 and CD33 an overall incidence of 4.3{\%} was found, with values ranging between 1.8{\%} for CD14 and 6.1{\%} for CD15. When the data were further dissected, a significantly higher incidence of co-expression was noted in null-ALL (15/70 cases = 21.4{\%}), compared to cases expressing a more mature immunophenotype, i.e. common-ALL (7/394 cases = 1.7{\%}) and T-ALL (1/68 cases = 1.4{\%}) (P <0.001). In null-ALL, 9/15 patients were infants, five of whom with the t(4;11); two further children also had a t(4;11). The clinical outcome of the 23 cases which co-expressed myeloid antigens was unfavourable. Only two of the 15 null-ALL, two of the seven common-ALL and the unique case with T-ALL are in fact in persistent first remission between 19 and 93 months from diagnosis. Though the overall incidence of childhood ALL expressing myeloid antigens is low, the evidence that this co-expression may be related to an unfavourable clinical course and that it more frequently occurs in null-ALL, particularly in the first year of life, suggests that the routine assessment of myeloid antigens may allow to identify a subgroup of childhoold ALL with a poor clinical outcome.",
author = "A. Cantu-Rajnoldi and C. Putti and M. Saitta and D. Granchi and R. Foa and R. Schiro and M. Castagni and C. Valeggio and M. Jankovic and R. Miniero and P. Paolucci and G. Basso",
year = "1991",
language = "English",
volume = "79",
pages = "40--43",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia

T2 - Relationship with the stage of differentiation and clinical significance

AU - Cantu-Rajnoldi, A.

AU - Putti, C.

AU - Saitta, M.

AU - Granchi, D.

AU - Foa, R.

AU - Schiro, R.

AU - Castagni, M.

AU - Valeggio, C.

AU - Jankovic, M.

AU - Miniero, R.

AU - Paolucci, P.

AU - Basso, G.

PY - 1991

Y1 - 1991

N2 - Co-expression of myeloid antigens on the leukaemic blast cells was evaluated in 532 children with a diagnosis of acute lymphoblastic leukaemia (ALL). Using a panel of monoclonal antibodies belonging to CD11b, CD13, CD14, CD15 and CD33 an overall incidence of 4.3% was found, with values ranging between 1.8% for CD14 and 6.1% for CD15. When the data were further dissected, a significantly higher incidence of co-expression was noted in null-ALL (15/70 cases = 21.4%), compared to cases expressing a more mature immunophenotype, i.e. common-ALL (7/394 cases = 1.7%) and T-ALL (1/68 cases = 1.4%) (P <0.001). In null-ALL, 9/15 patients were infants, five of whom with the t(4;11); two further children also had a t(4;11). The clinical outcome of the 23 cases which co-expressed myeloid antigens was unfavourable. Only two of the 15 null-ALL, two of the seven common-ALL and the unique case with T-ALL are in fact in persistent first remission between 19 and 93 months from diagnosis. Though the overall incidence of childhood ALL expressing myeloid antigens is low, the evidence that this co-expression may be related to an unfavourable clinical course and that it more frequently occurs in null-ALL, particularly in the first year of life, suggests that the routine assessment of myeloid antigens may allow to identify a subgroup of childhoold ALL with a poor clinical outcome.

AB - Co-expression of myeloid antigens on the leukaemic blast cells was evaluated in 532 children with a diagnosis of acute lymphoblastic leukaemia (ALL). Using a panel of monoclonal antibodies belonging to CD11b, CD13, CD14, CD15 and CD33 an overall incidence of 4.3% was found, with values ranging between 1.8% for CD14 and 6.1% for CD15. When the data were further dissected, a significantly higher incidence of co-expression was noted in null-ALL (15/70 cases = 21.4%), compared to cases expressing a more mature immunophenotype, i.e. common-ALL (7/394 cases = 1.7%) and T-ALL (1/68 cases = 1.4%) (P <0.001). In null-ALL, 9/15 patients were infants, five of whom with the t(4;11); two further children also had a t(4;11). The clinical outcome of the 23 cases which co-expressed myeloid antigens was unfavourable. Only two of the 15 null-ALL, two of the seven common-ALL and the unique case with T-ALL are in fact in persistent first remission between 19 and 93 months from diagnosis. Though the overall incidence of childhood ALL expressing myeloid antigens is low, the evidence that this co-expression may be related to an unfavourable clinical course and that it more frequently occurs in null-ALL, particularly in the first year of life, suggests that the routine assessment of myeloid antigens may allow to identify a subgroup of childhoold ALL with a poor clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=0026010416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026010416&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 40

EP - 43

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -